Al18F-octreotide

Phase 3Peptide

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Al18F-octreotide is one of 5 small molecule programs targeting Neuroendocrine Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine TumorRecruiting

Neuroendocrine TumorPhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Neuroendocrine Tumor

#DrugCompanyPhaseTrials

Lutathera

AAdvanced Accelerator Applications

Approved

1 2

Votrient

Novartis

Phase 2

1 3

Recombinant Human GM-CSF

EEastern Cooperative Oncology Group

Phase 3

1 4

Al18F-octreotide

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3

1 5

Alphamedix

OOrano Med LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuroendocrine Tumor1 trial

Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

Recruiting·—·Phase 2/3·NCT05749289·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Al18F-octreotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Al18F-octreotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Al18F-octreotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Institute and Hospital, Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Al18F-octreotide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News